Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neuropace, Inc. - Common Stock (NQ:NPCE)

12.86 +0.05 (+0.39%)
Streaming Delayed Price Updated: 12:38 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Neuropace, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
From NeuroPace, Inc.
Via Business Wire
News headline image
NeuroPace to Participate in Upcoming Healthcare Conferences
From NeuroPace, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
From Pomerantz LLP
Via GlobeNewswire
News headline image
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, Inc. - NPCE
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
From Pomerantz LLP
Via GlobeNewswire
News headline image
NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting
From NeuroPace, Inc.
Via GlobeNewswire
News headline image
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting
Three-year data from NeuroPace’s Post-Approval Study of the RNS® System in drug-resistant focal epilepsy to be shared in oral presentation 
From NeuroPace, Inc.
Via GlobeNewswire
News headline image
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
From NeuroPace, Inc.
Via GlobeNewswire
News headline image
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
From NeuroPace, Inc.
Via GlobeNewswire
News headline image
NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From NeuroPace, Inc.
Via GlobeNewswire
News headline image
NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration
From NeuroPace, Inc.
Via GlobeNewswire
News headline image
NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting
RNS System featured in over 50 Scientific Presentations and Posters 
From NeuroPace, Inc.
Via GlobeNewswire
News headline image
NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
From NeuroPace, Inc.
Via GlobeNewswire
News headline image
NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
From NeuroPace, Inc.
Via GlobeNewswire
News headline image
NeuroPace Announces RNS System Enhancements Designed to Streamline Care
From NeuroPace, Inc.
Via GlobeNewswire
News headline image
NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
From NeuroPace, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.